Gemigliptin (BioDeep_00000837979)
代谢物信息卡片
Gemigliptin
化学式: C18H19F8N5O2 (489.141093)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CC(CN(C1=O)CC(CC(=O)N2CCC3=C(C2)N=C(N=C3C(F)(F)F)C(F)(F)F)N)(F)F
InChI: InChI=1S/C18H19F8N5O2/c19-16(20)3-1-12(32)31(8-16)6-9(27)5-13(33)30-4-2-10-11(7-30)28-15(18(24,25)26)29-14(10)17(21,22)23/h9H,1-8,27H2/t9-/m0/s1
描述信息
A - Alimentary tract and metabolism > A10 - Drugs used in diabetes > A10B - Blood glucose lowering drugs, excl. insulins > A10BH - Dipeptidyl peptidase 4 (dpp-4) inhibitors
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C98086 - Dipeptidyl Peptidase-4 Inhibitor
C471 - Enzyme Inhibitor > C783 - Protease Inhibitor
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:134731
- KEGGdrug: D10502
- PubChem: 11953153
- DrugBank: DB12412
- ChEMBL: CHEMBL3707235
- CAS: 911637-19-9
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Youngmi Song, Hyekyung Yang, Juhee Kim, Yoonjin Lee, Sung-Ho Kim, In-Gu Do, Cheol-Young Park. Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy.
Molecular metabolism.
2023 Sep; 78(?):101806. doi:
10.1016/j.molmet.2023.101806. [PMID: 37739179] - Kyeong-Min Lee, Yeo Jin Hwang, Gwon-Soo Jung. Gemigliptin exerts protective effects against doxorubicin-induced hepatotoxicity by inhibiting apoptosis via the regulation of fibroblast growth factor 21 expression.
Biochemical and biophysical research communications.
2022 10; 626(?):135-141. doi:
10.1016/j.bbrc.2022.08.021. [PMID: 36049375] - Hojin Oh, Hai Duc Nguyen, In Mo Yoon, Byung-Ryong Ahn, Min-Sun Kim. Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system.
Scientific reports.
2021 10; 11(1):20938. doi:
10.1038/s41598-021-00418-z. [PMID: 34686738] - Thananda Trakarnvanich, Bancha Satirapoj, Swangjit Suraamornkul, Thanit Chirananthavat, Anoma Sanpatchayapong, Torpong Claimon. Effect of Dipeptidyl Peptidase-4 (DPP-4) Inhibition on Biomarkers of Kidney Injury and Vascular Calcification in Diabetic Kidney Disease: A Randomized Controlled Trial.
Journal of diabetes research.
2021; 2021(?):7382620. doi:
10.1155/2021/7382620. [PMID: 34697593] - Eunsol Yang, Hyounggyoon Yoo, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee. Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study.
Drug design, development and therapy.
2021; 15(?):651-658. doi:
10.2147/dddt.s288986. [PMID: 33628012] - Hee Seok Jung, Mi Seon Seo, Jin Ryeol An, Minji Kang, Ryeon Heo, Hongliang Li, Won-Kyo Jung, Il-Whan Choi, Eun-Hee Cho, Hongzoo Park, Young Min Bae, Won Sun Park. The vasodilatory effect of gemigliptin via activation of voltage-dependent K+ channels and SERCA pumps in aortic smooth muscle.
European journal of pharmacology.
2020 Sep; 882(?):173243. doi:
10.1016/j.ejphar.2020.173243. [PMID: 32535099] - Jung Beom Seo, Yeon Kyung Choi, Hye In Woo, Yun A Jung, Sungwoo Lee, Seunghyeong Lee, Mihyang Park, In Kyu Lee, Gwon Soo Jung, Keun Gyu Park. Gemigliptin Attenuates Renal Fibrosis Through Down-Regulation of the NLRP3 Inflammasome.
Diabetes & metabolism journal.
2019 12; 43(6):830-839. doi:
10.4093/dmj.2018.0181. [PMID: 30877711] - Sang Won Lee, Sang-In Park, SeungHwan Lee, Jae-Yong Chung, Kyung-Sang Yu. Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.
International journal of clinical pharmacology and therapeutics.
2019 Feb; 57(2):117-124. doi:
10.5414/cp203289. [PMID: 30574864] - Eunwoo Kim, Kyoung Ryun Park, In-Jin Jang, Kyung-Sang Yu, SeungHwan Lee. A Fixed-Dose Combination Of Gemigliptin And Rosuvastatin Exhibits Similar Pharmacokinetics, Pharmacodynamics, And Safety Compared To That Of A Loose Combination In Healthy Subjects.
Drug design, development and therapy.
2019; 13(?):3879-3885. doi:
10.2147/dddt.s197054. [PMID: 32009778] - Yong-Soon Cho, Shi Hyang Lee, Hyeong-Seok Lim, Kyun-Seop Bae. Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy Subjects.
Journal of Korean medical science.
2018 Oct; 33(41):e258. doi:
10.3346/jkms.2018.33.e258. [PMID: 30288156] - Sang Youb Han, Sun Ae Yoon, Byoung Geun Han, Sung Gyun Kim, Young-Il Jo, Kyung Hwan Jeong, Kook-Hwan Oh, Hyeong Cheon Park, Sun-Hee Park, Shin-Wook Kang, Ki-Ryang Na, Sun Woo Kang, Nam-Ho Kim, Younghwan Jang, Bogyeong Kim, Seonghye Shin, Dae Ryong Cha. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
Diabetes, obesity & metabolism.
2018 02; 20(2):292-300. doi:
10.1111/dom.13059. [PMID: 28719008] - Chang Ho Ahn, Kyung Ah Han, Jae Myung Yu, Joo Young Nam, Kyu Jeung Ahn, Tae Keun Oh, Hyoung Woo Lee, Dae Ho Lee, Jaetaek Kim, Choon Hee Chung, Tae Sun Park, Byung Joon Kim, Seok Won Park, Hyeong Kyu Park, Kwang Jae Lee, Sang-Wook Kim, Jeong Hyun Park, Kwan Pyo Ko, Chong Hwa Kim, Hyunjin Lee, Hak Chul Jang, Kyong Soo Park. Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, placebo-controlled study (TROICA study).
Diabetes, obesity & metabolism.
2017 05; 19(5):635-643. doi:
10.1111/dom.12866. [PMID: 28026912] - Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Tae-Seok Lim, Ki-Ho Song, Ki-Dong Yoo, Yu-Bae Ahn, Seung-Hyun Ko. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.
Lipids in health and disease.
2017 Apr; 16(1):58. doi:
10.1186/s12944-017-0443-4. [PMID: 28403877] - Sun A Yoon, Byoung G Han, Sung G Kim, Sang Y Han, Young I Jo, Kyung H Jeong, Kook H Oh, Hyeong C Park, Sun H Park, Shin W Kang, Ki R Na, Sun W Kang, Nam H Kim, Young H Jang, Seong H Shin, Dae R Cha. Efficacy, safety and albuminuria-reducing effect of gemigliptin in Korean type 2 diabetes patients with moderate to severe renal impairment: A 12-week, double-blind randomized study (the GUARD Study).
Diabetes, obesity & metabolism.
2017 04; 19(4):590-598. doi:
10.1111/dom.12863. [PMID: 28019072] - Chang Ho Ahn, Eun Ky Kim, Se Hee Min, Tae Jung Oh, Young Min Cho. Effects of gemigliptin, a dipeptidyl peptidase-4 inhibitor, on lipid metabolism and endotoxemia after a high-fat meal in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2017 03; 19(3):457-462. doi:
10.1111/dom.12831. [PMID: 27868366] - Soon-Youn Choi, Hye-Myung Ryu, Eun-Joo Oh, Ji-Young Choi, Jang-Hee Cho, Chan-Duck Kim, Yong-Lim Kim, Sun-Hee Park. Dipeptidyl peptidase-4 inhibitor gemigliptin protects against vascular calcification in an experimental chronic kidney disease and vascular smooth muscle cells.
PloS one.
2017; 12(7):e0180393. doi:
10.1371/journal.pone.0180393. [PMID: 28686724] - Seung Hee Choi, Jaechan Leem, In-Kyu Lee. Protective Effects of Gemigliptin, a Dipeptidyl Peptidase-4 Inhibitor, against Cisplatin-Induced Nephrotoxicity in Mice.
Mediators of inflammation.
2017; 2017(?):4139439. doi:
10.1155/2017/4139439. [PMID: 29317794] - Soo Lim, Kyung Ah Han, JaeMyung Yu, Parinya Chamnan, Eun Sook Kim, Kun-Ho Yoon, Sam Kwon, Min Kyong Moon, Kwan Woo Lee, Dong-Jun Kim, Mikyung Kim, Manaj Wongtanate, Eun Young Kim, Sung-Ho Kim, Moon-Kyu Lee. Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).
Diabetes, obesity & metabolism.
2017 01; 19(1):87-97. doi:
10.1111/dom.12787. [PMID: 27619558] - Da Rae Kim, Shin Yeong Lee, Jin Sug Kim, Yang Gyun Kim, Ju-Young Moon, Sang Ho Lee, Tae Won Lee, Chun Gyoo Ihm, Kyung Hwan Jeong. Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.
BioMed research international.
2017; 2017(?):7275109. doi:
10.1155/2017/7275109. [PMID: 28326327] - Sung-Ho Kim, Eunsoo Jung, Min Kyung Yoon, O Hwan Kwon, Dal-Mi Hwang, Dong-Wook Kim, Junghyun Kim, Sun-Mee Lee, Hyeon Joo Yim. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
European journal of pharmacology.
2016 Oct; 788(?):54-64. doi:
10.1016/j.ejphar.2016.06.016. [PMID: 27298192] - Ju-Young Moon, Jong Shin Woo, Jung-Woo Seo, Arah Lee, Dong Jin Kim, Yang-Gyun Kim, Se-Yeun Kim, Kyung Hye Lee, Sung-Jig Lim, Xian Wu Cheng, Sang-Ho Lee, Weon Kim. The Dose-Dependent Organ-Specific Effects of a Dipeptidyl Peptidase-4 Inhibitor on Cardiovascular Complications in a Model of Type 2 Diabetes.
PloS one.
2016; 11(3):e0150745. doi:
10.1371/journal.pone.0150745. [PMID: 26959365] - Hwan-Jin Hwang, Tae Woo Jung, Baek-Hui Kim, Ho Cheol Hong, Ji A Seo, Sin Gon Kim, Nan Hee Kim, Kyung Mook Choi, Dong Seop Choi, Sei Hyun Baik, Hye Jin Yoo. A dipeptidyl peptidase-IV inhibitor improves hepatic steatosis and insulin resistance by AMPK-dependent and JNK-dependent inhibition of LECT2 expression.
Biochemical pharmacology.
2015 Nov; 98(1):157-66. doi:
10.1016/j.bcp.2015.08.098. [PMID: 26297911] - Seon Ha Baek, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Ki Young Na. Effects of a DPP4 inhibitor on cisplatin-induced acute kidney injury: study protocol for a randomized controlled trial.
Trials.
2015 May; 16(?):239. doi:
10.1186/s13063-015-0772-4. [PMID: 26021829] - Sang-In Park, Howard Lee, Jaeseong Oh, Kyoung Soo Lim, In-Jin Jang, Jeong-Ae Kim, Jong Hyuk Jung, Kyung-Sang Yu. A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjects.
Drug design, development and therapy.
2015; 9(?):729-36. doi:
10.2147/dddt.s75980. [PMID: 25678778] - Eunsoo Jung, Junghyun Kim, Sung Ho Kim, Sanghwa Kim, Myung-Haing Cho. Gemigliptin, a novel dipeptidyl peptidase-4 inhibitor, exhibits potent anti-glycation properties in vitro and in vivo.
European journal of pharmacology.
2014 Dec; 744(?):98-102. doi:
10.1016/j.ejphar.2014.10.008. [PMID: 25448307] - J H Shon, N Kim, S J Park, M K Oh, E Y Kim, S H Lee, Y H Kim, J G Shin. Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15-0444).
Diabetes, obesity & metabolism.
2014 Oct; 16(10):1028-31. doi:
10.1111/dom.12292. [PMID: 24641348] - Yoon Kim, Unyong Kim, In Sook Kim, Sung-Hack Lee, Jaeick Lee, Dong-Hyun Kim, Hye Hyun Yoo. Absorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats.
Xenobiotica; the fate of foreign compounds in biological systems.
2014 Jul; 44(7):627-34. doi:
10.3109/00498254.2013.873156. [PMID: 24738939] - Namtae Kim, Lorna Patrick, Stuart Mair, Lloyd Stevens, Gill Ford, Vicky Birks, Sung-Hack Lee. Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.
Xenobiotica; the fate of foreign compounds in biological systems.
2014 Jun; 44(6):522-30. doi:
10.3109/00498254.2013.865856. [PMID: 24304170] - Dongseong Shin, Young Min Cho, SeungHwan Lee, Kyoung Soo Lim, Jeong-Ae Kim, Ji-Yung Ahn, Joo-Youn Cho, Howard Lee, In-Jin Jang, Kyung-Sang Yu. Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Clinical drug investigation.
2014 Jun; 34(6):383-93. doi:
10.1007/s40261-014-0184-3. [PMID: 24627290] - Hye Sook Min, Jung Eun Kim, Mi Hwa Lee, Hye Kyoung Song, Young Sun Kang, Mi Jin Lee, Ji Eun Lee, Hyun Wook Kim, Jin Joo Cha, Young Yoon Chung, Young Youl Hyun, Jee Young Han, Dae Ryong Cha. Dipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstruction.
Laboratory investigation; a journal of technical methods and pathology.
2014 Jun; 94(6):598-607. doi:
10.1038/labinvest.2014.50. [PMID: 24687121] - E J Rhee, W Y Lee, K W Min, V K Shivane, A R Sosale, H C Jang, C H Chung, I S Nam-Goong, J A Kim, S W Kim. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
Diabetes, obesity & metabolism.
2013 Jun; 15(6):523-30. doi:
10.1111/dom.12060. [PMID: 23320436] - S J Yang, K W Min, S K Gupta, J Y Park, V K Shivane, S U Pitale, P K Agarwal, A Sosale, P Gandhi, M Dharmalingam, V Mohan, U Mahesh, D M Kim, Y S Kim, J A Kim, P K Kim, S H Baik. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2013 May; 15(5):410-6. doi:
10.1111/dom.12042. [PMID: 23170990] - Yook-Hwan Noh, Hyeong-Seok Lim, Seok-Joon Jin, Mi Jo Kim, Yo Han Kim, Hye Ryoung Sung, Hee Youn Choi, Kyun-Seop Bae. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Clinical therapeutics.
2012 May; 34(5):1182-94. doi:
10.1016/j.clinthera.2012.04.001. [PMID: 22534255] - E J Rhee, W Y Lee, K H Yoon, S J Yoo, I K Lee, S H Baik, Y K Kim, M K Lee, K S Park, J Y Park, B S Cha, H W Lee, K W Min, H Y Bae, M J Kim, J A Kim, D K Kim, S W Kim. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2010 Dec; 12(12):1113-9. doi:
10.1111/j.1463-1326.2010.01303.x. [PMID: 20977584] - Kyoung Soo Lim, Joo-Youn Cho, Bo-Hyung Kim, Jung-Ryul Kim, Hwa-Sook Kim, Dong-Kyu Kim, Sung-Ho Kim, Hyeon Joo Yim, Sung-Hack Lee, Sang-Goo Shin, In-Jin Jang, Kyung-Sang Yu. Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidase IV inhibitor, after multiple dosing in healthy volunteers.
British journal of clinical pharmacology.
2009 Dec; 68(6):883-90. doi:
10.1111/j.1365-2125.2009.03376.x. [PMID: 20002082] - Kyoung Soo Lim, Jung-Ryul Kim, Yun-Jung Choi, Kwang-Hee Shin, Kyu-Pyo Kim, Jang-Hee Hong, Joo-Youn Cho, Hyun-Suk Shin, Kyung-Sang Yu, Sang-Goo Shin, O Hwan Kwon, Dal-Mi Hwang, Jeong-Ae Kim, In-Jin Jang. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Clinical therapeutics.
2008 Oct; 30(10):1817-30. doi:
10.1016/j.clinthera.2008.10.013. [PMID: 19014837]